Unlocking the Value of Combination Therapies
![unlocking the value of combination therapies](https://www.ohe.org/wp-content/uploads/2024/07/unlocking-the-value-of-combination-therapies-scaled.jpeg)
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference…
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference to the challenges of HTA in the UK. A failure to consistently consider all ultra-rare disease medicines under the HST process could lead to inequalities in access and health outcomes for patients with ultra-rare conditions.
Ethical and Economic Issues in the Appraisal of Medicines for Ultra-Rare Conditions